Skip to main content

Table 1 Distribution of the responses to the case vignette

From: International variation in the management of severe COVID-19 patients

Numbers (%) or median (interquartile ranges)

Total, 1001 respondents

1. Admission to the ICU of a previously healthy 39-year-old man with severe COVID-19

 Direct admission to the ICU

55%

 Admission in an intermediate care unit

34.2%

 Delayed admission to the ICU because of lack of bed

1.3%

 Patient stays in the emergency department

0.8%

 Patient admitted in the wards

8.8%

2. Initial oxygenation strategy

 I increase the oxygen flow to 15 l/min keeping the face mask

24.2%

 I change the mask for a Venturi mask

17.5%

 I start CPAP or noninvasive ventilation

25.5%

 I start high flow nasal oxygen

47.1%

 I intubate the patient right away

7.4%

 I add prone positioning on spontaneous breathing

37.9%

3. Optimizing oxygenation in a patient with a PF ratio of 84 4 h after intubation

 I will give neuromuscular blockade for 24–48 h

50.9%

 I increase and titrate PEEP to optimize recruitment

61.4%

 I prone the patient immediately

73.2%

 I am considering ECMO immediately

4.7%

 Let us wait a little bit

9.9%

4. Regarding the initial antibiotics

 All my patients receive a broad anti-bacterial agent

45.3%

 I only give broad anti-bacterial agent to febrile patients

11%

 I only give broad anti-bacterial agent if CRP or PCT are high

4.2%

 I only give broad anti-bacterials to patients with structural lung diseases

35.8%

 I never give broad anti-bacterial agent in severe viral infections

3.7%

5. Regarding initial anti-viral therapy, several options are possible

 The level of evidence is so low that there is nothing I can give

48.9%

 I prescribe (hydroxy)chloroquine

42.7%

 I prescribe lopinavir/ritonavir

17.0%

 I prescribe remdesivir

15%

 I prescribe another anti-viral drug

4.6%

6. Are you starting an anti-inflammatory therapy?

 

 No

52.4%

 Yes IL-1 or IL-6 blockade

24.8%

 Yes, complement blockade

1.4%

 Yes, steroids

31.5%

 Yes, another anti-inflammatory drug

2.4%